Sector News

Bristol-Myers Squibb appoints Paul Biondi as SVP

October 19, 2015
Life sciences

Bristol-Myers Squibb Co. has appointed Paul Biondi as the company’s senior vice president, head of Business Development.

The announcement was made Thursday, Oct. 15. On the same day, the company also agreed to collaborate and exclusively license Five Prime Therapeutics Inc. to develop and commercialize Five Prime’s antibody program for cancer treatment.

As Biondi assumes the role of Bristol-Myers Squibb’s SVP, he is to report to Chief Financial Officer Charlie Bancroft and will lead the development of strategic collaborations and seek scientific innovations in various fields including commercial, development, discovery and technology platforms to complement the company’s internal R&D pipeline, Market Watch has learned.

“Paul has established himself as a dynamic and collaborative leader at Bristol-Myers Squibb and made significant contributions over the past 10 years to our success in R&D and business development,” Bancroft said. “With deep knowledge of our R&D strategy and portfolio, strong business expertise and understanding of the healthcare landscape, Paul is the ideal leader to continue our pursuit of external innovation that helps Bristol-Myers Squibb develop and deliver transformational medicines for patients with serious diseases.”

Meanwhile, Bristol-Myers Squibb and Five Prime has entered an over a billion licensing deal. According to Reuters, Five Prime will receive $350 million upfront and potential development as well as regulatory milestone payouts of up to $1.74 billion.

The more than a billion dollar payment is for the program that includes the drug component codenamed “FPA008,” which is in Phase 2 development belonging to a new class of drugs called immunotherapies. The drug is designed to harness body’s own immune system to fight cancer.

Both Bristol-Myers Squibb and Five Prime Therapeutics Inc. announced that the global deal includes additional double-digit royalties on future sales and an option to co-promote in the United States.

Aside from Five Prime’s internal pipeline assets in immuno-oncology, which partnered with Bristol-Myers Squibb, it also operates BioPharmaceuticals. It products are manufactured by its companies in America, Puerto Rico and six foreign countries, which are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession, Ledger Gazette noted.

Source: JobsnHire

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”